Empowering the discovery of novel target-disease associations via machine learning approaches in the open targets platform.

Journal: BMC bioinformatics
PMID:

Abstract

BACKGROUND: The Open Targets (OT) Platform integrates a wide range of data sources on target-disease associations to facilitate identification of potential therapeutic drug targets to treat human diseases. However, due to the complexity that targets are usually functionally pleiotropic and efficacious for multiple indications, challenges in identifying novel target to indication associations remain. Specifically, persistent need exists for new methods for integration of novel target-disease association evidence and biological knowledge bases via advanced computational methods. These offer promise for increasing power for identification of the most promising target-disease pairs for therapeutic development. Here we introduce a novel approach by integrating additional target-disease features with machine learning models to further uncover druggable disease to target indications.

Authors

  • Yingnan Han
    Translational Sciences, Sanofi US, Framingham, MA, 01701, USA.
  • Katherine Klinger
    Translational Sciences, Sanofi US, Framingham, MA, 01701, USA.
  • Deepak K Rajpal
    From the Department of Integrative Biology and Physiology, University of California, Los Angeles (Y.Z., Q.M., X.Y.); and Target Sciences Computational Biology (US), GSK, King of Prussia, PA (J.C., J.M.F., D.K.R.). xyang123@ucla.edu deepak.k.rajpal@gsk.com.
  • Cheng Zhu
    Translational Sciences, Sanofi US, Framingham, MA, 01701, USA. Cheng.Zhu@sanofi.com.
  • Erin Teeple
    Translational Sciences, Sanofi US, Framingham, MA, 01701, USA. Erin.Teeple@sanofi.com.